Towards an effective HIV vaccine by Rogier Sanders and Godelieve de Bree (Amsterdam UMC)
There is not yet a vaccine against the second deadliest infection in the world after tuberculosis: HIV. Rogier Sanders and Godelieve de Bree of the Amsterdam UMC are optimistic about the possibility of developing one now. It’s for the first time that a vaccine is being developed in one hospital (Amsterdam UMC) from the design phase to the safety and efficacy studies in healthy volunteers. It’s also unique that these studies for an HIV vaccine are being done in the Netherlands.
However, actually making the vaccine for testing in humans is very expensive. Rogier and Godelieve are trying to make that happen and are now looking for funding. The potential impact on treating HIV through this vaccine is enormous!
Explore other Stories:
Valorisation in medical technology
These are exciting times for Dave Koolbergen, congenital cardiac surgeon at AMC. With his company Haermonics he hopes to bring a new technology to market for postoperative pericardial flushing. It was developed upon his observation that after heart surgery often the removal of accumulated blood and clots can be achieved by flushing the pericardial space […]
Story of Sue Gibbs (ACTA / Amsterdam UMC)
How to make an impact with your research and what does it take to go from idea to product or service. Watch the video of Sue Gibbs, regenerative medicine ACTA / Amsterdam UMC. She explains how her research contributed in making a lasting impact.
Improved HIV vaccine candidates activating naïve B- cells expressing germline bNAb precursors
Improved HIV vaccine candidates activating naïve B- cells expressing germline bNAb precursors – Licensing opportunity (PDF)